(MENAFN- ProactiveInvestors)
’ () research collaborator Professor Erica Fletcher from the University of Melbourne has been awarded a $355000 Australian Research Council (ARC) Linkage grant.
The funds will be used to detail the precise effects its 2RT laser has on cells cell populations and the body as a whole.
It will provide fundamental knowledge on the impact of 2RT™on cell biology of immune cells and cell signalling pathways in the retina.
The work will also give Ellex’s researchers a better understanding of the mechanism of action and potential uses of the 2RT laser currently in use in clinical trials for the treatment of early-stage age-related macular degeneration.
During FY2015 sales of commercial 2RT units increased to early adopters and research collaborators in Holland Germany Italy France New Zealand and Australia.
As of 15th June 2015 these commercial 2RT units had been used to perform approximately 1500 procedures on 940 patients. These patients and treatments are in addition to the patients being treated in the LEAD trial.
The potential market for AMS across the U.S. UK Germany France Spain Italy and Japan will almost double in value to $10.1 billion by 2023 from $5.1 billion in 2013.
Proactive Investors Australia is the market leader in producing news articles and research reports on ASX emerging companies with distribution in Australia UK North America and Hong Kong / China.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.